14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
WGS vs CDNA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, CareDx, Inc. (CDNA) is the stronger overall head-to-head candidate over GeneDx Holdings Corp. (WGS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). WGS carries a Unified Composite Score of 49.5/100 (HOLD) at $51.02 (40.6x Forward P/E, -13.7% operating margin), whereas CDNA carries 24.5/100 (STRONG SELL) at $73.72 (47.1x Forward P/E, 1.6% operating margin).
Composite vs. Pillar Nuance: While WGS currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. CDNA 24.5/100 STRONG SELL), CDNA captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (1.6% vs. -13.7% operating margin) and revenue trajectory (+39.3% vs. +5.4% YoY).
Technical & Structure Timing Caution: WGS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.8); meanwhile CDNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Diagnostics & Research value chain with $4.1B market capitalization and 1.6% operating margin.
OpEx & R&D Reinvestment69.4% of Rev ($345M)
90D Engineering Disclosures0 Published
Investor FAQ WGS vs CDNA Key Questions & Quantitative Answers
As of Nov 16, 2026, CareDx, Inc. (CDNA) is the stronger overall head-to-head candidate over GeneDx Holdings Corp. (WGS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). WGS carries a Unified Composite Score of 49.5/100 (HOLD) at $51.02 (40.6x Forward P/E, -13.7% operating margin), whereas CDNA carries 24.5/100 (STRONG SELL) at $73.72 (47.1x Forward P/E, 1.6% operating margin). Composite vs. Pillar Nuance: While WGS currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. CDNA 24.5/100 STRONG SELL), CDNA captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (1.6% vs. -13.7% operating margin) and revenue trajectory (+39.3% vs. +5.4% YoY). Technical & Structure Timing Caution: WGS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.8); meanwhile CDNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CDNA leads the Growth & Scale pillar: WGS posts +5.4% YoY revenue growth and +0.0% YoY earnings growth on $461M TTM revenue (68.8% gross margin, -13.7% operating margin), compared with CDNA at +39.3% YoY revenue growth and N/A YoY earnings growth on $497M TTM revenue (71.0% gross margin, 1.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), WGS cumulative revenue shifted +115.0% while CDNA shifted +375.0%. In operating R&D and SG&A reinvestment, WGS deploys 82.5% of Rev ($380M) (0 90-day corporate R&D disclosures) versus 69.4% of Rev ($345M) (0 disclosures) for CDNA.
WGS screens cheaper on headline valuation multiples. WGS trades at 40.6x Forward P/E, 38.8x Trailing P/E, N/M PEG, and 3.7x EV/Revenue (-22.0% FCF margin), whereas CDNA trades at 47.1x Forward P/E, 32.9x Trailing P/E, N/M PEG, and 7.8x EV/Revenue (12.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against WGS (-41.4% ROE) versus CDNA (33.0% ROE) capital efficiency.
In options market volatility and institutional positioning, WGS carries 102.3% implied volatility (21st %ile, Compressed (<25th %ile)), a 7.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.74β · 111% Vol realized risk). By comparison, CDNA carries 56.8% implied volatility (18th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.21β · 98% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.